Research Papers:

Adjuvant treatment with tumor-targeting Salmonella typhimurium A1-R reduces recurrence and increases survival after liver metastasis resection in an orthotopic nude mouse model

Takashi Murakami, Yukihiko Hiroshima, Ming Zhao, Yong Zhang, Takashi Chishima, Kuniya Tanaka, Michael Bouvet, Itaru Endo and Robert M. Hoffman _

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:41856-41862. https://doi.org/10.18632/oncotarget.6170

Metrics: PDF 1430 views  |   HTML 1724 views  |   ?  


Takashi Murakami1,2,3, Yukihiko Hiroshima1,2,3, Ming Zhao1, Yong Zhang1, Takashi Chishima3, Kuniya Tanaka3, Michael Bouvet2, Itaru Endo3 and Robert M. Hoffman1,2

1 AntiCancer, Inc., San Diego, California, USA

2 Department of Surgery, University of California, San Diego, California, USA

3 Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Japan

Correspondence to:

Robert M. Hoffman, email:

Keywords: liver metastasis, colon cancer, RFP, nude mice, orthotopic models

Received: August 07, 2015 Accepted: October 04, 2015 Published: October 19, 2015


Colon cancer liver metastasis is often the lethal aspect of this disease. Well-isolated metastases are candidates for surgical resection, but recurrence is common. Better adjuvant treatment is therefore needed to reduce or prevent recurrence. In the present study, HT-29 human colon cancer cells expressing red fluorescent protein (RFP) were used to establish liver metastases in nude mice. Mice with a single liver metastasis were randomized into bright-light surgery (BLS) or the combination of BLS and adjuvant treatment with tumor-targeting S. typhimurium A1-R. Residual tumor fluorescence after BLS was clearly visualized at high magnification by fluorescence imaging. Adjuvant treatment with S. typhimurium A1-R was highly effective to increase survival and disease-free survival after BLS of liver metastasis. The results suggest the future clinical potential of adjuvant S. typhimurium A1-R treatment after liver metastasis resection.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6170